Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript

Operator

Good morning, and welcome to Beam Therapeutics Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Beam’s request.

I would now like to turn the call over to Holly Manning, Vice President of Investor Relations and External Communications.

Holly Manning
Vice President of Investor Relations & External Communications

Thank you, operator. Good morning, everyone, and welcome to Beam’s conference call to review top line clinical data from the Phase I/II trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency. You can access slides for today’s call by going to the Investors section of our website, beamtx.com.

With me on the call today with prepared remarks are John Evans, our Chief Executive Officer; Dr. Amy Simon, our Chief Medical Officer; Dr. Jeff Teckman from St. Louis University; and Dr. Giuseppe Pino Ciaramella, our President.

Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements for purposes of the safe harbor provision under